Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Raises Sales And Earnings But Admits ‘Tough’ Q2

Organic And Inorganic Moves Drive Growth

Executive Summary

Privately-owned Stada provided little insight into the exact mechanics of its operations for the first six months of 2020 but nevertheless said it had enjoyed an “above-market sales and earnings increase.” However, a raft of one-off expenses bit into the German firm’s profitability.

You may also be interested in...



Generics Industry Counts Cost Of Stormy Second Quarter

As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.

Stada Faces Damages On German Pemetrexed Reversal

In its half-year report, Stada has confirmed it continues to face the threat of damages from Eli Lilly, following its ‘at-risk’ launch in Germany of an alternative to the originator’s Alimta in July 2018.

Stada Faces Damages On German Pemetrexed Reversal

In its half-year report, Stada has confirmed it continues to face the threat of damages from Eli Lilly, following its ‘at-risk’ launch in Germany of an alternative to the originator’s Alimta in July 2018.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel